Tempus AI, based in Chicago, Illinois, went public on June 14, 2024, providing next-generation diagnostics through genomics and AI applications aimed at personalizing medicine. Its primary product, Next, uses machine learning to enhance oncology and cardiology care.
Andrew Polovin sold 13,135 shares of TEM on 18 March at $47.37 per share, worth a total of $622K. They now own 157,927 TEM shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
